

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-73. (Canceled)

Claim 74. (Previously Presented): A pharmaceutical formulation comprising:

- (a) a pharmaceutically acceptable carrier; and
  - (b) a protein that:
    - (1) binds to a normally glycosylated FLT3 receptor;
    - (2) has at least 95% amino acid sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, and SEQ ID NO:8;
- and
- (3) preserves hematopoietic progenitor cells.

Claim 75. (Canceled)

Claim 76. (Previously Presented): The pharmaceutical formulation of claim 84, wherein said subject is a human undergoing treatment for cancer.

Claim 77. (Previously Presented): The pharmaceutical formulation of claim 84, wherein said therapeutic treatment is selected from the group consisting of radiotherapy, chemotherapy, or a combination of radiotherapy and chemotherapy.

Claim 78. (Previously Presented): The pharmaceutical formulation of claim 77, wherein said chemotherapy comprises administration of a chemotherapeutic selected from the group consisting of cytarabine, doxorubicin, and 5-fluorouracil.

Claim 79. (Previously Presented): The pharmaceutical formulation of claim 74 or 84, wherein said pharmaceutical formulation is suitable for parenteral administration.

Claim 80. (Previously Presented): The pharmaceutical formulation of claim 79, wherein said parenteral administration is selected from the group consisting of intravenous, intra-arterial, subcutaneous, intramuscular, intraperitoneal and intra-marrow administration.

Claim 81. (Previously Presented): The pharmaceutical formulation of claim 74 or 84, wherein said protein comprises the amino acid sequence of SEQ ID NO: 2.

Claim 82. (Previously Presented): The pharmaceutical formulation of claim 74 or 84, wherein said protein comprises the amino acid sequence of SEQ ID NO:6.

Claim 83. (Previously Presented): The pharmaceutical formulation of claim 74 or 84, wherein said protein comprises the amino acid sequence of SEQ ID NO: 8.

Claim 84. (Previously Presented): A pharmaceutical formulation comprising:

- (a) a pharmaceutically acceptable carrier; and
- (b) an effective amount of a protein that:
  - (1) binds to a normally glycosylated FLT3 receptor;
  - (2) has at least 95% amino acid sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, and SEQ ID NO: 8; and
  - (3) reduces a progenitor cell depleting activity in a subject undergoing a therapeutic treatment having progenitor cell depleting activity.

Claim 85. (New): The pharmaceutical formulation of claim 74 or 84, wherein said protein comprises an amino acid sequence having 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 2.

Claim 86. (New): The pharmaceutical formulation of claim 74 or 84, wherein said protein comprises an amino acid sequence having 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:6.

Claim 87. (New): The pharmaceutical formulation of claim 74 or 84, wherein said protein comprises an amino acid sequence having 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 8.